GENFIT Reports First Half-Year 2023 Financial Results and Pr

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in June 2023, paving the way to: a potential submission to the

Related Keywords

Zurich , Züsz , Switzerland , United Kingdom , France , Massachusetts , United States , Cambridge , Cambridgeshire , Paris , France General , Seal Rock , French , Steven Hildemann , Pascal Prigent , Sandra Silvestri , Tom Huijbers , Sakina Sayah Jeanne , Euronext , Service Transition Agreement , Board Of Directors The Company , Group Cash , European Medicines Agency , Research Translational Science , Head Of Global Medical Affairs , Patient Affairs , Company Annual Shareholder Meeting , Nasdaq , Cash Flow Of The Group , Financiers French Financial Markets Authority , Research As , Exchange Commission , Us Securities Exchange Commission , Transition Services Agreement , International Financial Reporting Standards , Uncertainties Of The Company , Drug Administration , Phepatology Communications , Celloram Inc , Research Tax Credit , Chronic Liver Failure , Investigational New Drug , Digestive Disease Week , Seal Rock Therapeutics , Reactive Oxygen Species , Hepatic Encephalopathy , Urea Cycle Disorders , Organic Acidemias , Inborn Errors , Non Invasive Test , Annual Shareholder Meeting , Executive Vice President , Chief Medical Officer , Global Medical Affairs , Patient Safety , Executive Vice President Research , Translational Science , European Medicines , Orphan Drug Designation , License Agreement , Transition Services , Consolidated Statement , Year Business , Financial Report , Registration Document , French Autorit , Des March , Condensed Consolidated Statements , Financial Position , Cash Flow , Half Year Business , Cash Flows , Primary Biliary Cholangitis , Nasdaq Global Select Market , Private Securities Litigation Reform Act , French Financial Markets Authority ,